本研究旨在评估胆胰管镜辅助内镜下黏膜切除术（CA-EMR）治疗胆胰管内病变的可行性和安全性。发达。 2023年11月至2024年4月期间，我们对2名胆囊息肉患者、1名胆总管（CBD）肿瘤性病变患者和1名主胰管（PD）肿瘤性病变患者进行了CA-EMR。记录技术成功率和不良事件。所有4次CA-EMR程序均成功执行。术后病理显示2例患者为炎性胆囊息肉，1例为CBD低度上皮内瘤变（LGIN），1例为导管内乳头状粘液性肿瘤（IPMN）。 IPMN患者术后出现轻度胰腺炎，经保守治疗后康复。其余3例CA-EMR手术均未出现不良事件。本研究初步证实了CA-EMR治疗胆胰管内病变的可行性和安全性。Thieme。版权所有。

This study aimed to assess the feasibility and safety of performing cholangiopancreatoscopy-assisted endoscopic mucosal resection (CA-EMR) for biliopancreatic intraductal lesions.Special electrocautery snares and injection needles that can pass through the working channel of a single-operator cholangiopancreatoscope (SOC) were developed. Between November 2023 and April 2024, we performed CA-EMR for 2 patients with gallbladder polyps, 1 patient a neoplastic lesion in the common bile duct (CBD) and 1 patient with a neoplastic lesion in the main pancreatic duct (PD). The technical success rate and adverse events were recorded.All 4 CA-EMR procedures were performed successfully. Postoperative pathology revealed inflammatory gallbladder polyps in 2 patients, low grade intraepithelial neoplasia (LGIN) of CBD in 1 patient and intraductal papillary mucinous neoplasm (IPMN) in 1 patient. The patient with IPMN experienced mild postoperative pancreatitis and recovered after conservative treatment. No adverse events were encountered in the other 3 CA-EMR procedures.This study preliminarily confirmed the feasibility and safety of CA-EMR for treating biliopancreatic intraductal lesions.Thieme. All rights reserved.